Inventor · disambiguated record
Catherine Scholz
Also filed as: SCHOLZ CATHERINE · SCHOLZ CATHERINE R · SCHOLZ CATHERINE ROSE
19 granted patents·17 pending applications·138 citations·filing 2006–2025
95Inventor score
Files withKURA ONCOLOGY INC15MILLENNIUM PHARM INC11TAKEDA PHARMACEUTICALS CO6EISAI R&D MAN CO LTD2DILUZIO WILLOW1
Top patents by PatentIndex Score
36 records- 0195US12053526B2Methods for treatment using anti-alpha4beta7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 6, 2024·5 cites·34 claims
- 0295US10143752B2Methods of treating ulcerative colitisMILLENNIUM PHARM INC·Filed 2016·Granted Dec 4, 2018·21 cites·5 claims
- 0395US10004808B2Methods of treating ulcerative colitisMILLENNIUM PHARM INC·Filed 2016·Granted Jun 26, 2018·20 cites·4 claims
- 0495US9663579B2Formulation for anti-α4β7 antibodyMILLENNIUM PHARM INC·Filed 2016·Granted May 30, 2017·20 cites·6 claims
- 0594US9956215B1Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted May 1, 2018·5 cites·30 claims
- 0694US9764033B2Formulation for anti-α4β7 antibodyDILUZIO WILLOW·Filed 2012·Granted Sep 19, 2017·32 cites·33 claims
- 0792US10426767B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Oct 1, 2019·3 cites·34 claims
- 0892US9707221B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2016·Granted Jul 18, 2017·8 cites·23 claims
- 0991US12286479B2Treatment with anti-α4β7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Apr 29, 2025·3 cites·30 claims
- 1091US12171832B2Methods of treating ulcerative colitisTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Dec 24, 2024·2 cites·12 claims
- 1191US2025041424A1Methods for treatment using anti-alpha4beta7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1290US2025000981A1Methods for treatment using anti-alpha4beta7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1389US10292979B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted May 21, 2019·4 cites·28 claims
- 1489US10137121B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Nov 27, 2018·2 cites·30 claims
- 1588US10022364B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Jul 17, 2018·4 cites·14 claims
- 1687US11207314B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Dec 28, 2021·1 cites·17 claims
- 1787US10980793B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2019·Granted Apr 20, 2021·1 cites·30 claims
- 1887US2025034263A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2024·Application pending·0 cites
- 1986US10335404B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Jul 2, 2019·3 cites·24 claims
- 2086US2025295786A1Methods for treatment using anti-alpha4beta7 antibodyTAKEDA PHARMACEUTICALS CO·Filed 2025·Application pending·0 cites
- 2185US10471055B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2016·Granted Nov 12, 2019·3 cites·28 claims
- 2282US2023089412A1Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 2381US2022370617A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2022·Application pending·0 cites
- 2480US2023312727A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2022·Application pending·0 cites
- 2576US11124839B2Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2017·Granted Sep 21, 2021·1 cites·34 claims
- 2672US11541045B2Methods of treating cancer with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2018·Granted Jan 3, 2023·0 cites·39 claims
- 2771US2019231878A1Formulation for anti-alpha4beta7 antibody and methods of treatmentMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 2869US2018289811A1Methods of treating inflammatory bowel diseaseMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 2967US2019076532A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2017·Application pending·0 cites
- 3065US2021381063A1Methods of treating cancer patients with farnesyltransferase inhibitorsKURA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 3163US2018346578A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 3263US2018327497A1Formulation for anti-alpha4beta7 antibodyMILLENNIUM PHARM INC·Filed 2018·Application pending·0 cites
- 3362US2024384356A1Biomarkers for sting agonists and methods of using the sameEISAI R&D MAN CO LTD·Filed 2022·Application pending·0 cites
- 3459US2024043928A1Biomarkers for myelodysplastic syndrome (mds) and methods of using the sameEISAI R&D MAN CO LTD·Filed 2021·Application pending·0 cites
- 3555US2007041938A1Stable aqueous solutions of granulocyte macrophage colony-stimulating factorSCHERING AG·Filed 2006·Application pending·0 cites
- 3643US2022071941A1Therapies for squamous cell carcinomasKURA ONCOLOGY INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Catherine Scholz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →